Literature DB >> 21146242

IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.

Carlo Fabris1, Edmondo Falleti, Annarosa Cussigh, Davide Bitetto, Elisabetta Fontanini, Sara Bignulin, Sara Cmet, Ezio Fornasiere, Elisa Fumolo, Stefano Fangazio, Andrea Cerutti, Rosalba Minisini, Mario Pirisi, Pierluigi Toniutto.   

Abstract

BACKGROUND & AIMS: A single nucleotide polymorphism (rs12979860 C/T) 3kb upstream of the interleukin 28B (IL-28B) gene was shown to be associated with hepatitis C clearance. We verified whether this association also translates into a different genotype distribution at the end of the disease trajectory.
METHODS: A RFLP-PCR technique was used to genotype 412 patients with cirrhosis due to hepatitis C (n=199), hepatitis B (n=75), alcohol (n=110), and other causes (n=28), of whom 256 underwent liver transplantation (OLT). Hepatocellular carcinoma (HCC) was demonstrated in the native liver of 85 OLT patients, 52 with viral cirrhosis, and 33 with non-viral cirrhosis respectively. A group of 292 patients (235 HCV and 57 HBV positive) with mild chronic hepatitis and 344 healthy subjects served as controls.
RESULTS: A significant difference (p=0.0005) was observed in IL-28B rs12979860 genotype frequencies between patients with viral cirrhosis (C/C=99, C/T=137, T/T=38) and those with non-viral cirrhosis (C/C=72, C/T=58, T/T=8). Patients with HCV related cirrhosis carried more frequently the T/T genotype in comparison to mild hepatitis C or HBV-related cirrhosis. IL-28B rs12979860 genotype frequencies were C/C=23, C/T=50, T/T=12 among OLT patients with cirrhosis complicated by HCC, and C/C=79, C/T=78, T/T=14 among patients with cirrhosis not complicated by HCC (p<0.005).
CONCLUSIONS: IL-28B rs12979860 C/T polymorphism T allele is more prevalent in patients with viral cirrhosis due to HCV in comparison to other aetiologies and to patients with mild chronic hepatitis C. Among OLT patients, carriage of this allele seems to augment the risk of developing HCC.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146242     DOI: 10.1016/j.jhep.2010.07.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  71 in total

1.  Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus.

Authors:  Michael O Baclig; Karen G Reyes; Cynthia A Mapua; Juliet Gopez-Cervantes; Filipinas F Natividad
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

2.  IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.

Authors:  Vito Di Marco; Fabrizio Bronte; Vincenza Calvaruso; Marcello Capra; Zelia Borsellino; Aurelio Maggio; Maria Concetta Renda; Lorella Pitrolo; Maria Carmela Lo Pinto; Michele Rizzo; Flavia Fiorenza; Calogera Gerardi; Stefania Grimaudo; Antonietta Di Cristina; Massimo Levrero; Antonio Craxì
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 3.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

4.  Metabolomics study of type 2 diabetes using ultra-performance LC-ESI/quadrupole-TOF high-definition MS coupled with pattern recognition methods.

Authors:  Ai-hua Zhang; Hui Sun; Guang-li Yan; Ye Yuan; Ying Han; Xi-jun Wang
Journal:  J Physiol Biochem       Date:  2013-08-24       Impact factor: 4.158

5.  Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment.

Authors:  L Nosotti; A Petrelli; D Genovese; S Catone; C Argentini; S Vella; A Rossi; G Costanzo; A Fortino; L Chessa; L Miglioresi; C Mirisola
Journal:  J Immigr Minor Health       Date:  2017-08

6.  Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients.

Authors:  Abdolvahab Alborzi; Tayebeh Hashempour; Javad Moayedi; Zahra Musavi; Gholamreza Pouladfar; Shahin Merat
Journal:  Med Microbiol Immunol       Date:  2017-02-18       Impact factor: 3.402

7.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

8.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Authors:  A J Muir; L Gong; S G Johnson; M T M Lee; M S Williams; T E Klein; K E Caudle; D R Nelson
Journal:  Clin Pharmacol Ther       Date:  2013-10-04       Impact factor: 6.875

9.  Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

Authors:  Mazen Noureddin; Elizabeth C Wright; Harvey J Alter; Shauna Clark; Emmanuel Thomas; Richard Chen; Xiongce Zhao; Cathy Conry-Cantilena; David E Kleiner; T Jake Liang; Marc G Ghany
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

10.  IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.

Authors:  Mostafa K El Awady; Noha G Bader El Din; Ashraf Tabll; Yaser El Hosary; Ashraf O Abdel Aziz; Hesham El Khayat; Mohsen Salama; Tawfeek H Abdelhafez
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.